OncoTAb, Inc., a University of North Carolina at Charlotte (UNCC) spin-out company, announced it has been awarded $300,000 by the National Cancer Institute (NCI) to initiate development of a targeted radionuclide therapy for triple negative breast cancer. In addition to preclinical work, the company will continue developing its patented antibody for therapeutic use in humans under this award.